MRI 10 or LbL capsules for drug delivery 11 . The conjugation method comprises three stages:
Expression and purification of the scFv-LPETG, which specifically binds to activated platelets, and a control scFv mut -LPETG, as well as the transpeptidase sortase A (Steps 1-46) Functionalization of particles with a GGG nucleophile to facilitate the enzymatic reaction ( Step 47A(i-xiii) and
Step 47B(xi-xvii)) Incubation of GGG-tagged particles with sortase A and scFv-LPETG, and scFv mut -LPETG, respectively ( Step 47A(xiv-xvi) and Step 47B(xviii))
Experimental design
Single-chain antibodies (scFv). The scFv used for our studies targets the activated glycoprotein IIb/IIIa (α IIb β 3 , CD41/CD61) receptor, the most abundant molecule on the platelet surface 17 . This integrin receptor undergoes a conformational change upon platelet activation, and it exposes epitopes that are unique to the activated state 18 . Platelets have a crucial role in atherogenesis, thrombosis, inflammation and immune responses 19, 20 . As such, activated platelets are highly attractive target epitopes for molecular imaging and drug delivery. scFv variants. In our research, we have used three scFv variants: a nonblocking anti-ligand-induced binding sides (LIBS) antibody 21, 22 for our imaging application, the function-blocking antibody SCE5 (refs. 23,24) for the drug-delivery applications, and a nonbinding antibody as a control for all experiments. If a diagnostic application is required, we recommend the use of the nonblocking anti-LIBS scFv. If a therapeutic application is desired (anticoagulation, antiinflammation or thrombolysis), we recommend the use of the function-blocking scFv.
We added a sortase A LPETG recognition sequence to the C-terminal end of the scFv, with an accompanying hexahistidine tag (His 6 -tag), to facilitate purification and detection. This results in a scFv-LPETGGGH 6 entity, which is suitable as a substrate for sortase A. The last few amino acids of the C terminus are not engaged in antigen binding or part of the complementaritydetermining regions. Hence, manipulations of this region • • • typically retain antibody functionality. Furthermore, the positioning of the LPETG motif before the His 6 -tag ensures cleavage of the His 6 -tag during the enzymatic reaction. Conveniently, this facilitates the removal of the purification tag from the final product after the coupling reaction. It is advised that the LPETG be as close to the C terminus as possible to allow sufficient access for the sortase A enzyme.
Conjugation partners, e.g., iron oxide microparticles and LbL capsules. This protocol has been used successfully to conjugate scFv to GGG-modified commercial iron oxide microparticles (MPIOs) for MRI. MRI, a noninvasive and widely used imaging modality, which is continuously evolving toward new clinical applications by virtue of its enhanced spatial resolution 25, 26 , is capable of imaging vessels at a submillimeter level [27] [28] [29] . However, despite this, MRI still lacks the sensitivity to detect small focal areas of disease in the vascular setting, such as intravascular thrombi. This makes molecular imaging of cells or cellular receptors challenging. Iron oxide particles, especially MPIOs, have a much stronger signal compared with small particles of iron oxide such as small, ultrasmall and very ultrasmall particles of iron oxide. Therefore, the use of MPIOs has the potential to overcome sensitivity limitation in MRI by providing a potent negative contrast in T2-star-weighted imaging [30] [31] [32] [33] . These particles cause local magnetic field inhomogeneity and signal distortions within an area up to 50 times the size of the particle depending on the MRI method. We describe the detailed functionalization and bioconjugation of MPIOs to recombinant scFvs for molecular MRI.
We have also established a protocol for the development of scFv-functionalized low-fouling nano-and micro-sized capsules, for use as therapeutic drug-delivery vehicles 34, 35 . Polymeric capsules can protect healthy tissue from the side effects of toxic chemotherapy agents or protect a sensitive payload, such as nucleic acids or proteins, from physiological degradation 36 . A promising method for creating such delivery vehicles is LbL assembly 37, 38 , which enables the generation of particles in varying type, shape and size, including variable intrinsic properties such as responsiveness to external conditions and degradability [39] [40] [41] . LbL assembly can be performed in aqueous solutions, which is important for sensitive biomolecules, and a range of polymers can be used to tune the composition, permeability, stability and surface functionality of the capsules. By using the described methods, many nano-and microparticles can be functionalized with scFvs as long as a reactive surface group is present for the attachment of the sortase peptide. To allow sufficient access to particle surface groups, a spacer (e.g., a polyethylene linker) is recommended.
Preparation of LbL delivery vehicles.
As starting material for the LbL capsules described here, we use low-fouling biocompatible materials such as PEG and poly(N-vinylpyrrolidone) (PVPON), which have minimal immunogenicity and nonspecific cellular binding or uptake, making them ideal for biological applications 42 . Furthermore, these capsules may be directly cross-linked and hence covalently stabilized in one step by infiltration of a cross-linker rather than cross-linking individual layers upon deposition. As a platform technology, the generation of the capsules described here is independent of the polymer type. As such, a variety of cross-linkers (including cleavable cross-linkers such as disulfide bonds or enzyme-specific peptide segments, as well as noncleavable cross-linkers) may be used to control capsule biodegradation. To control the size of the capsules as required, the amount of polymer, cross-linker, peptide and other reagents can be scaled in proportion to the surface area. For example, the total surface area of the 1-µm sample will have three times the surface area of the 3-µm samples. Therefore, the 1-µm sample will require three times the amount of polymer, cross-linker and peptide. To cross-link the individual polymer layers, as well as to functionalize the capsule surface with the sortase A substrate, we use click chemistry as introduced by Sharpless and co-workers 43 , which has already markedly influenced the modern synthesis of advanced materials, owing to ease and versatility. Click reactions are highly quantitative, with minimal or no by-products, and they are orthogonal to other functionalities. Owing to its many advantages, including its high selectivity under mild conditions, we chose the copper (I)-catalyzed 1,3-dipolar cycloaddition between alkyne and azide 44 .
Advantages and limitations of the sortase A coupling approach
Other enzymatic conjugation techniques have been developed, with the most prominent being the biotin ligase-AviTag enzyme technology. This approach uses the stable binding between biotin and (strept)avidin, but it avoids possible inactivation of proteins of interest by random biotinylation associated with chemical labeling. The AviTag sequence with only 15 aa (GLNDIFEAQKIEWHE) contains the optimal peptide sequence for biotinylation 45 . AviTag can be cloned into either the N terminus 46 or the C terminus 47 of a fusion protein, or at other internal protein locations 48 , as long as the peptide domain forms an accessible surface-exposed loop. However, several disadvantages exist. Although the AviTag is not much larger than the sortase A tag, its conjugation partner (strept)avidin is considerably larger than the GGG motif used by sortase A. This large size (56-69 kDa) may affect protein function 49 . In addition, (strept)avidin is potentially immunogenic and may bind endogenous biotin. Although ketone-modified biotin molecules have recently been developed, allowing conjugation of ketone-tagged proteins with hydrazide-or hydroxylaminefunctionalized molecules 46 , this approach lacks sensitivity because of the specific kinetics of hydrazide labeling.
Another enzymatic conjugation technique is the transglutaminase-catalyzed formation of peptide bonds between the γ-carboxyamide group of an intact protein-bound glutamine with a variety of primary amines, particularly the ε-amino group of lysine 50 . Similarly to sortase A, the recognition sequences (Q-tags) such as PKPQQFM 51 and GQQQLG 52 are small and very specific, and they can be genetically introduced at the N terminus of target proteins. Microbial transglutaminase from Streptomyces mobaraensis has already been used for labeling of scFvs 53 and for site-specific modification and PEGylation of different pharmaceutical proteins for clinical applications 54 . With its high selectivity, mild reaction conditions and highly stable covalent bond, transglutaminase conjugation has many features comparable to sortase A. However, in the absence of the canonical Q-tag, labeling of non-Q-tagged proteins may occur 50 , unlike the use of sortase A, which is specific for the LPXTG tag.
A key advantage of sortase A bioconjugation is the requirement of two short amino acid motifs (LPXTG and GGG) that are easily incorporated into substrates of interest by either chemical synthesis or genetic engineering. This minimizes potential issues with protein expression and purification and avoids adverse immunogenic complications, which is a major hurdle for translation of the AviTag system. In contrast to the transglutaminase technology, the high specificity of sortase A allows coupling of relatively crude protein preparations, thus allowing shortening of protein purification protocols and minimal ligation of contaminants 55 . Finally, sortase A is straightforward to produce in substantial quantities, thereby ensuring cost efficiency 56 .
A major drawback of the sortase A coupling approach is the relatively slow reaction kinetics, ranging from 1-3 h to (in some cases) overnight incubation periods to achieve a high conjugation yield 56 . However, the use of mutagenesis and maturation studies may improve the efficiency of the reaction up to 140-fold using a directed evolution strategy involving a yeast display 57 . Another drawback is the difficulty to push the reaction equilibrium toward the product side, as the product still displays the LPXTG sortase A recognition sequence 58 . This reverse reaction leads to constant turnover of formed product. In addition, owing to the nature of the sortase A reaction, introduction of LPXTG and GGG motifs to the target is largely restricted to the C terminus and the N terminus, respectively. 
MaterIals
! cautIon Always use personal protective equipment (gloves, eye protection, lab coat and closed shoes) in a laboratory environment. For all items marked with '! cautIon' , please take extra care and use these chemicals in a fume hood. More information can be found in the MSDS.  crItIcal Depending on the measuring equipment available, unless otherwise specified, in any given section, we advise that you weigh the closest amount to the value specified in the protocol and dilute accordingly to reach the desired concentration. Molar concentrations are given as final concentrations.  crItIcal Filter-sterilize all buffers by passing each through a 0. 22 
Overall, this protocol demonstrates the use of sortase A for bioconjugation of recombinant single-chain variable fragments in a selective and site-specific manner, which allows the production of targeted imaging contrast particles and drug-delivery vehicles suitable for molecular imaging and targeted drug therapy. The sortase A reaction is universally applicable, and the addition of sortase A to the toolbox for recombinant antibody modification has the potential for substantial scientific and clinical impact. The bisazide cross-linker is required to conjugate the alkyne-functionalized co-polymers after layer deposition. analytical data 13 Gel loading dye, blue (New England BioLabs, cat. no. B7021) Glycerol (Sigma-Aldrich, cat. no. G5516) Host-optimized DNA from GeneArt (Invitrogen) encoding sortase A enzyme (recombinant variant with 59-aa N-terminal deletion) Host-optimized DNA from GeneArt (Invitrogen) with C-terminal LPETG tag N-terminal of a His6-tag for the scFvs anti-LIBS 21, 22 , SCE5 and mutMA2 (refs. 23,24) . All constructs from GeneArt contained the required 
Box 2 | Synthesis of alkyne-functionalized co-polymers poly(MEO 2 MA-co-OEGMA-co-PgTEGMA) PEG Alk • tIMInG 14 d
The alkyne-functionalized co-polymers poly(MEO 2 MA-co-OEGMA-co-PgTEGMA) PEG Alk is required as one of the building blocks of the LbL capsules. First, the individual monomers need to be synthesized. Next, the polymer is generated from the monomer building blocks, and it is used to make the final LbL capsules. procedure synthesis of 2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol 1. Prepare a THF (50 ml) solution of triethylene glycol (11.6 g, 76 mmol) in a 100-ml round-bottom flask and cool it to 0 °C using an ice/water bath. 2. Slowly add sodium hydride (2.0 g, 50 mmol, 60% (wt/vol) dispersion in mineral oil). 3. Stir the mixture for 20 min. 4. Add a dropping funnel to the flask containing propargyl bromide (4.2 ml, 38 mmol). 5. Add the propargyl bromide dropwise to the reaction over 15 min. 6. Stir the reaction mixture at room temperature for 20 h. 7. Concentrate the final product using rotary evaporation. 8. Dissolve the concentrated product in ~20 ml of DCM, and then wash it successively with saturated sodium hydrogen carbonate (NaHCO 3 ; 2 × 50 ml) and water (50 ml). 9. Dry the organic phase over MgSO 4 (~1 g) and then remove the solid residue by filtration. 10. Concentrate the crude product using rotary evaporation. 11. Purify the crude product by column chromatography, eluting with a 2:3 mixture of n-hexane and ethyl acetate to give 2-(2-(2-(prop-2-ynyloxy)ethoxy)ethoxy)ethanol as a light yellow oil.  pause poInt This product can be stored in the refrigerator for several months if it is kept in a sealed container. Integrity can be assessed by NMR.
synthesis of 2-(2-(2-(3-(trimethylsilyl)-prop-2-ynyloxy)ethoxy)ethoxy)ethanol
12. Add triethylene glycol alkyne (3.39 g, 18 mmol, made above) to a 50-ml round-bottom flask along with silver chloride (0.24 g, 1.8 mmol) suspended in 25 ml of anhydrous DCM (dried by distillation). 13. Add 1,8-diazabicyclo(5.4.0)undec-7-ene (3.5 g, 23 mmol). 14. Attach a sealed 10-ml dropping funnel to the round-bottom flask containing chlorotrimethylsilane (2.8 g, 26 mmol). 15. Stir this mixture at 40 °C in a constant-temperature oil bath while adding chlorotrimethylsilane dropwise. 16 . Stir the reaction mixture for 24 h at 40 °C. 17. Cool the mixture to room temperature and dilute it with 200 ml of n-hexane. Wash the organic phase successively with NaHCO 3 (2 × 50 ml), 0.1 M HCl (2 × 50 ml) and water (50 ml) using a 100-ml dropping funnel. 18. Dry the organic phase using MgSO 4 and remove the solid residue by filtration. 19 . Concentrate the crude product by rotary evaporation. 20. Purify the crude product by column chromatography, by eluting with an 8:1 mixture of n-hexane and ethyl acetate to obtain 2-(2-(2-(3-(trimethylsilyl)-prop-2-ynyloxy)ethoxy)ethoxy)ethanol as a light yellow liquid.  pause poInt This product can be stored in the refrigerator for several months if it is kept in a sealed container. Integrity can be assessed by NMR.
(continued)
Box 2 | (continued) synthesis of 2-(2-(2-(3-(trimethylsilyl)prop-2-ynyloxy)ethoxy)-ethoxy)ethyl methacrylate (tMspgteGMa)
21. Measure out TMS-alkyne triethylene glycol (2.0 g, 7.7 mmol, as made in the previous section) and triethylamine (0.81 g, 8 mmol) in small glass vials and add them to a two-necked round-bottom flask containing 50 ml of DCM. 22. Dissolve methacryloyl chloride (0.78 ml, 8 mmol) in 10 ml of DCM and add it into a 50-ml equilibrating dropping funnel. Place the funnel in one neck with a septum at the top containing an outlet needle. The second neck should also contain a septum with a needle that is slowly bubbling nitrogen gas into the solution. 23. Cool the mixture to 0 °C using an ice/water bath. 24. Add the methacryloyl chloride solution very slowly over 1 h with constant stirring.  crItIcal step Care must be taken to add this slowly, as excess reactants can cause polymerization to occur. 25. Stir the reaction mixture at room temperature for 18 h, and then filter to remove triethylamine hydrochloride. 26. Wash the filtrate with saturated NaHCO 3 (2 × 50 ml) and water (50 ml) using a 200-ml separating funnel. 27. Dry the organic phase using MgSO 4 (1 g), and then filter it to form a yellowish brown solution. 
Box 3 | Synthesis of poly(N-vinyl pyrrolidone-ran-propargyl-acrylate) PVPON Alk • tIMInG 7 d
The alkyne-functionalized co-polymers poly(N-vinyl pyrrolidone-ran-propargyl-acrylate) PVPON Alk is required as one of the building blocks of the LbL capsules. procedure 1. Run propargyl acrylate and 1-vinyl-2-pyrrolidone down a 5-cm basic alumina column to completely remove the inhibitor. Collect the purified monomer at the bottom of the column. 2. Measure out propargyl acrylate (7.5 mg, 6.8 × 10 −2 mmol) and 1-vinyl-2-pyrrolidone (0.99 g, 9.0 mmol) exactly using a five-figure balance, and place it in a 5-ml glass vial. 3. Measure out the phthalimidomethyl xanthate reversible addition-fragmentation chain transfer agent (6.32 mg, 2.2 × 10 −2 mmol) and azobisisobutyronitrile (0.18 mg, 1.1 × 10 −3 mmol) exactly and place them in another glass vial. 4. Add 2 ml of dioxane to each vial, dissolve the contents and then transfer them into a Schlenk tube. 5. To purge the mixture of oxygen, four freeze-thaw cycles are required on a Schlenk line, which involves freezing the sample in liquid nitrogen and opening the system up to vacuum for 5 min. After evacuation, close the taps and warm the sample to release all of the gas trapped in the solution. The process is repeated three times, thereby increasing the evacuation time to 10, 20 and then 45 min. For the last cycle, heating is not removed, the sample is closed and removed from the Schlenk line. This step should completely remove the oxygen from the reaction, which is important as this will affect the polymerization reaction. 6. Place the polymerization reaction in a constant oil bath at 60 °C for 80 min. 7. After polymerization, the reaction is dialyzed in Milli-Q water for 6 d using a 10-kDa membrane. The water is exchanged daily during this period. 8. Freeze-dry the final product to form a fluffy yellowish powder.
analytical data
Use gel permeation chromatography for characterization. The polymer should show an average molar mass of ~16.5 kDa with a polydispersity of 1.3. proceDure transformation of scFv-lpetG and sortase a into Escherichia coli • tIMInG 2-3 h + overnight incubation 1| Centrifuge the microcentrifuge tubes at 9,000g on a benchtop centrifuge (Eppendorf 5424) for 30 s at room temperature.
2|
Add nuclease-free water to the lyophilized plasmid DNA to obtain a final concentration of 100 ng/µl.
3|
Thaw NEB Turbo competent E. coli cells on wet ice for 10 min.  crItIcal step Temperature and timing of thawing are important for the outcome of the transformation efficacy. Do not leave the cells standing for more than 30 min before use.
4|
Add 100 ng of plasmid DNA onto thawed cells, and then carefully flick the tube five times.  crItIcal step Do not vortex, as this will greatly reduce the transformation efficiency and damage the bacteria.
5|
Place the cell mixture on wet ice for 30 min.  crItIcal step Do not mix.
6|
Heat-shock the cells for exactly 30 s at 42 °C.  crItIcal step Do not mix.  crItIcal step The temperature and timing of the heat-shock step are crucial and specific to the transformation volume and vessel.
7|
Return the cells to ice for 4 min.  crItIcal step Do not mix. 
9|
Place the cells at 37 °C for 60 min, shaking vigorously at 250 r.p.m. in a bacterial incubator.
10|
Warm the ampicillin-supplemented LB agar plates to 37 °C.
11|
Plate 100 µl of cells onto an LB agar plate and allow them to grow overnight at 37 °C in a bacterial incubator.  crItIcal step Keep your laboratory bench area sterile by working near a flame from a Bunsen burner.
? trouBlesHootInG  pause poInt After overnight incubation, the plates should be sealed with Parafilm, and they may be stored for up to 4 weeks in a cold room or a refrigerator.
Growing of transformed E. coli in cultures and Dna extraction • tIMInG 1 h + overnight culture + 1 d 12| Pipette 5.5 ml of ampicillin-supplemented LB medium into 50-ml clear plastic centrifuge tubes.
13| From the ampicillin-supplemented LB agar plate, which has been growing overnight at 37 °C, inoculate the ampicillin-supplemented LB medium with single bacterial colonies using a plastic pipette tip.  crItIcal step Be careful when picking the bacterial colony to avoid contamination with other colonies.
14|
Place the plastic centrifuge tubes at 37 °C overnight (12 to 18 h) in a bacterial incubator, shaking vigorously at a 30° angle. After incubation, check for growth, which is characterized by a cloudy haze in the medium.
15|
For long-term storage of bacteria, create a glycerol stock of cells. Add 500 µl of the overnight culture to 500 µl of 50% (vol/vol) glycerol in a 2-ml screw-top tube or cryovial and gently mix. Shake the glycerol stock before freezing (five or six times), making sure that it is one uniform solution with no layers present.  crItIcal step Snap-top tubes are not recommended, as they can open unexpectedly at −80 °C.
16|
Freeze the glycerol stock tube at −80 °C.  crItIcal step Make sure that the glycerol stocks tubes are stored at −80 °C. The stock is stable for years; however, repetitive freeze and thaw cycles may reduce the shelf life.
17|
To recover bacteria from your glycerol stock, scrape some of the frozen bacteria from the top using a sterile pipette tip and add to the 37 °C ampicillin-supplemented LB medium.  crItIcal step Do not allow the glycerol stock to fully thaw.
18|
Pellet the cells by centrifuging the remaining 5 ml of bacterial culture at 3,700g for 10 min at 4 °C. Remove the clear supernatant.
 pause poInt Bacterial pellets may be frozen at −80 °C for several weeks.
19| Purify the plasmid DNA using the commercially available kit (Qiagen miniprep or equivalent), according to the manufacturer's instructions.  pause poInt Elutions of the plasmid DNA may be stored at −20 °C for several months.
20|
Measure the amount of DNA obtained from the preparations using a UV-vis spectrophotometer (NanoDrop 2000c or equivalent). 22| Add 4 µl of 6× gel loading dye to the samples and load them on a 1% (wt/vol) agarose gel along with a 1-kb DNA ladder. Size separation is performed using an electrophoresis tank at 100 V for 30 min.
Molecular cloning of constructs into pet20(+) vector

23|
Place the gel on an electrophoresis imager (Bio-Rad or equivalent) and photograph it.
24|
Determine the size of the digested construct (scFv-LPETG inserts are imaged near the 1-kb marker, the sortase A insert is imaged at the 1-kb mark and the digested vector pET20b(+) is imaged just above the 3-kb marker).
25|
Use a clean scalpel blade and carefully cut around the area of the targeted size. Place the cut gel portion into labeled 1.5-ml microcentrifuge tubes.
26| Extract DNA using a gel extraction kit (QIAquick or equivalent), according to the manufacturer's instructions.  pause poInt Eluted plasmid DNA can be stored at −20 °C for several months.
27|
Measure the amount of DNA obtained from the preparations using a UV-vis spectrophotometer (NanoDrop 2000c or equivalent).
28|
To ligate the digested DNA, prepare a 10-µl ligation reaction using 1 µl of T4 buffer and 1 µl of T4 DNA ligase. Add the DNA of the insert and the vector at a 1:3 (mol:mol) ratio and ligate at 16 °C for 1 h, and then at 4 °C overnight.
29|
Transform the ligation reaction to NEB Turbo competent E. coli cells, as described in Step 3.
30|
To confirm the correct sequence, isolate DNA as described before and send it to a commercial DNA sequencing company to determine the success of cloning (primers used: T7 promoter, 5′-TAATACGACTCACTATAGGG-3′ and T7 terminator, 5′-GCTAGTTATTGCTCAGCGG-3′). 
34|
Centrifuge the cells in 250-ml centrifuge bottles at 6,000g for 15 min at 4 °C.  pause poInt Bacterial pellets may be frozen at −80 °C for several weeks.
35|
Discard the supernatant and weigh the cell pellet. Per gram of pellet, resuspend with 3 ml of BugBuster master mix.
36|
Incubate the mixture for 15 min at room temperature while rocking gently.
37|
Centrifuge the mixture at 15,000g for 30 min at 4 °C.
38|
Collect the supernatant for purification over Ni-NTA Superflow columns on the FPLC system. Set the detector to 280 nm and the flow rate to 1 ml/min. All constructs contain the His 6 -tag, which enables purification using the Ni-NTA columns.
39|
Equilibrate the Ni-NTA column with 10 ml of binding/wash buffer.
40|
Apply the clear supernatant. UV absorption will increase.
41|
Wash the column with binding/wash buffer (0% imidazole) until protein UV absorption returns to baseline.
42|
Increase the proportion of imidazole solution (250 mM) to 8% (vol/vol). A wash peak with unspecific protein will appear, and this material can be discarded. Wash until protein UV absorption returns back to baseline.
43|
Elute the proteins from the column by increasing the proportion of imidazole solution from 20-250 mM (100%). Collect the peak fractions.
44| Place the fractions of purified proteins into a SnakeSkin dialysis tubing and dialyze them against PBS for 4 h at 4 °C. Change the buffer and dialyze overnight at 4 °C.  crItIcal step Avoid freeze-thaw cycles, as sortase A and scFvs are negatively affected and lose activity.  pause poInt The protein may be stored at −80 °C for several months. In the first step, the polymer layers are deposited onto the silica core particle; the different layers up to the dark blue layer indicate this. To stabilize the particles before removing the core and the cross-linking, additional layers are added (up to the dark red layer). Next, the internal layers (up to the dark blue one) are cross-linked using the biazide cross-linker and click chemistry. Finally, the core is removed along with the non-cross-linked protective layers. 
antIcIpateD results
The particles before and after conjugation can be best characterized by size using dynamic light scattering or qNano examinations to determine the size and hydrodynamic diameter. If LbL particles are not formed or if the antibody is not properly installed, please carefully check the protocol and consult the corresponding troubleshooting sections. Iron oxide particles functionalized with anti-LIBS scFv bind to GPIIb/IIIa on immobilized activated platelets, whereas iron oxide particles with control antibody do not bind (Fig. 2) . LbL capsules functionalized with scFv bind to GPIIb/IIIa on activated platelets in a thrombus, whereas LbL capsules with control antibody do not bind (Fig. 4) . Targeting of both particle systems can also be examined by using flow cytometry against activated platelets or by using a ligand-tracer system. 
